[Canthaxanthine retinopathy: 1. Clinical study in 51 consumers].
Canthaxanthine, a non-provitamin A carotenoid, has been marketed in Canada since March 1979 as a skin-tanning agent. Fifty-one individuals who ingested from 3.6 to 66 g of the drug within a 24-month period were ophthalmologically evaluated. Six of them had deposits in the ocular fundus that appeared to be related to ingestion of the substance, but no functional impairment could be detected.
D000284:Administration, Oral; D000328:Adult; D016644:Canthaxanthin; D002338:Carotenoids / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000187:drug effects
D002338:Carotenoids; D016644:Canthaxanthin
La rétinopathie à la canthaxanthine: 1. Etude clinique de 51 consommateurs.